FDA Neurology Clinical Team Leader Departure May Be Mountain Disguised As Molehill

Attention to the departure of neurology reviewer Ron Farkas from FDA has focused on what it means for Sarepta’s eteplirsen application, but there are larger regulatory environment issues that deserve more scrutiny.